secwatch.observer — SEC 8-K summary
======================================

Issuer:     Foghorn Therapeutics Inc. (FHTX)
CIK:        0001822462
Form:       8-K
Filed at:   2022-08-17T23:59:59+00:00
Accession:  0001628280-22-023096
Event type: leadership
Sentiment:  neutral
Materiality: 0.20
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Foghorn Therapeutics elects B. Lynne Parshall as Class III Director
-------------------------------------------------------------------

- B. Lynne Parshall elected to Board effective Aug 16, 2022; term expires at 2023 annual meeting.
- Appointed Chair of the Audit Committee.
- Awarded option to purchase 32,000 shares vesting equally over three years.
- Compensated per non-employee director policy; no related-party transactions disclosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1822462/000162828022023096/0001628280-22-023096-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1822462/000162828022023096/fhtx-20220816.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-023096

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer